Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer.
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Colorectal Neoplasms
/ drug therapy
Extracellular Matrix
/ metabolism
Extracellular Matrix Proteins
/ metabolism
Fluorouracil
/ administration & dosage
Humans
Leucovorin
/ administration & dosage
Liver Neoplasms
/ drug therapy
Male
Mass Spectrometry
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Neoplasms, Second Primary
/ drug therapy
Organoplatinum Compounds
/ administration & dosage
Proteome
/ metabolism
CRC
CRLM
Colorectal cancer
Colorectal liver metastasis
ECM
ECM signatures
Extracellular matrix
Metachronous liver metastasis
Prognostic factor
Proteomics
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
14
07
2020
accepted:
08
10
2020
pubmed:
26
10
2020
medline:
25
5
2021
entrez:
25
10
2020
Statut:
ppublish
Résumé
Colorectal cancer (CRC) patients suffer from the second highest mortality among all cancer entities. In half of all CRC patients, colorectal cancer liver metastases (CRLM) can be observed. Metastatic colorectal cancer is associated with poor overall survival and limited treatment options. Even after successful surgical resection of the primary tumor, metachronous liver metastases occur in one out of eight cases. The only available curative intended treatment is hepatic resection, but metachronous CRLM frequently recur after approximately 1 year. In this study, we performed a proteome analysis of three recurrent liver metastases of a single CRC patient by mass spectrometry. Despite surgical resection of the primary CRC and adjuvant chemotherapy plus cetuximab treatment, the patient developed three metachronous CRLM which occurred consecutively after 9, 21 and 31 months. We identified a set of 1132 proteins expressed in the three metachronous CRLM, of which 481 were differentially regulated, including 81 proteins that were associated with the extracellular matrix (ECM). 56 ECM associated proteins were identified as upregulated in the third metastasis, 26 (46%) of which were previously described as negative prognostic markers in CRC, including tenascin C, nidogen 1, fibulin 1 and vitronectin. These data may reflect an ascending trend of malignancy from the first to the third metachronous colorectal cancer liver metastasis. Additionally, the results indicate different ECM phenotypes for recurrent metachronous metastasis, associated with different grades of malignancy and highlights the importance of individual analysis of molecular features in different, consecutive metastatic events in a single patient.
Identifiants
pubmed: 33099724
doi: 10.1007/s10585-020-10058-8
pii: 10.1007/s10585-020-10058-8
pmc: PMC7666585
doi:
Substances chimiques
Extracellular Matrix Proteins
0
Organoplatinum Compounds
0
Proteome
0
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
649-656Références
Front Oncol. 2020 Mar 13;10:335
pubmed: 32232008
Sci Rep. 2016 Jul 15;6:29765
pubmed: 27416752
J Cancer Res Clin Oncol. 2001;127(3):193-9
pubmed: 11260865
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
pubmed: 2673568
BMC Bioinformatics. 2012;13 Suppl 16:S12
pubmed: 23176165
Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):583-592
pubmed: 31659112
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Biochim Biophys Acta. 1989 Feb 24;990(2):101-8
pubmed: 2465025
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Medicine (Baltimore). 2016 Feb;95(8):e2924
pubmed: 26937938
Semin Cell Dev Biol. 2019 May;89:157-166
pubmed: 29964200
Front Mol Biosci. 2020 Jan 31;6:160
pubmed: 32118030
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Int J Mol Sci. 2020 Feb 19;21(4):
pubmed: 32092871
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Br J Cancer. 2017 Oct 24;117(9):1360-1370
pubmed: 29065427
J Biol Chem. 2019 Jan 4;294(1):281-289
pubmed: 30409905
Clin Exp Metastasis. 2019 Jun;36(3):171-198
pubmed: 30972526
Neoplasma. 2006;53(5):372-83
pubmed: 17013531
Nat Biotechnol. 2010 Dec;28(12):1248-50
pubmed: 21139605
J Dtsch Dermatol Ges. 2014 Nov;12(11):1012-9
pubmed: 25307562
Euroasian J Hepatogastroenterol. 2017 Jul-Dec;7(2):166-175
pubmed: 29201802
Cell Metab. 2018 Jun 05;27(6):1249-1262.e4
pubmed: 29706565
Oncotarget. 2016 Oct 25;7(43):69829-69843
pubmed: 27634880
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Cell Mol Gastroenterol Hepatol. 2019;7(4):783-802
pubmed: 30831320
Br J Surg. 2012 Sep;99(9):1278-83
pubmed: 22864889
BMC Cancer. 2014 Jul 18;14:518
pubmed: 25037231
Ann Surg. 2006 Aug;244(2):254-9
pubmed: 16858188
FASEB J. 2004 May;18(7):816-27
pubmed: 15117886